SCHEMBL4923947

SCHEMBL4923947

COc1ccc2ccccc2c1-c1c(P(C)c2ccccc2)ccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.65
KMT2A Q03164 7/20 0.45
MEN1 O00255 5/20 0.45
NISCH Q9Y2I1 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 1/20 0.43
NQO1 P15559 1/20 0.42
HPGD P15428 3/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.36
NQO2 P16083 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923948 1.00 MAPT (0.65) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL2918270 0.87 MAPT (0.41) MAPTALDH1A1RAB9ANQO1HPGD
SCHEMBL1606348 0.87 MAPT (0.67) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL29834220 0.87 MAPT (0.67) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL29496547 0.87 MAPT (0.67) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL998182 0.80 MAPT (1.00) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL29428410 0.80 MAPT (1.00) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL12446367 0.78 MAPT (0.54) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL29511657 0.78 MAPT (0.67) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL2017985 0.78 MAPT (0.67) MAPTKMT2AMEN1NISCHSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8471067-B2 Stereoselective preparation of P-chiral four-co-ordinated phosphorus compound (o-Tolylphenylmethylphosphine oxide) by reacting chiral alcohol, chiral amine or chiral thiol, with P-chiral three-co-ordinated phosphorus compound, in presence of electrophile UNIVERSITY COLLEGE DUBLIN (IE) 2013-06-25 US disclosed
US-8471067-B2 Stereoselective preparation of P-chiral four-co-ordinated phosphorus compound (o-Tolylphenylmethylphosphine oxide) by reacting chiral alcohol, chiral amine or chiral thiol, with P-chiral three-co-ordinated phosphorus compound, in presence of electrophile UNIVERSITY COLLEGE DUBLIN (IE) 2013-06-25 US disclosed
US-20080255391-A1 Chiral Phosphorus Compounds UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND (IE) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255391-A1 Chiral Phosphorus Compounds PHOSPHO1, PNKP, PTMS MAPT 2418/4885KMT2A 3836/4885MEN1 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.